Viatris | VTRS - Ebit



Viatris reported $185.4M in EBIT for its fiscal quarter ending in June of 2025.


Ebit Change Date
Adcock Ingram Holdings ZAR 541.46M 52.57M Jun/2023
Celltrion KRW 242.47B 93.05B Jun/2025
Cspc Pharmaceutical CNY 1.51B 748.2M Mar/2025
Dianthus Therapeutics USD -34927000 3.01M Jun/2025
Divis Laboratories Ltd 6.17B 2.48B Jun/2025
Kangmei Pharma CNY 16.43M 19.69M Jun/2025
Knight Therapeutics CAD 3.2M 1.29M Sep/2024
Laboratorios Farma EUR 27.48M 95.85M Jun/2025
Malin Corporation EUR -2200000 800K Jun/2023
Medical Developments International AUD -12124000 3.97M Jun/2023
Neuren Pharmaceuticals AUD 171.1M 159.25M Dec/2024
Organigram Holdings CAD -2105000 9.2M Jun/2025
Pharma Mar EUR 24.15M 27.24M Jun/2025
Qiagen NV USD 134.43M 9.77M Jun/2025
Sartorius EUR 161.8M 1.8M Jun/2025
Sino Biopharmaceutical CNY 3.42B 453.21M Jun/2023
Tilray USD -42218000 5.65M Nov/2024
Viatris USD 185.4M 628M Jun/2025
Zz Pientze Pharmaceu 485.72M 705.85M Jun/2025